Fred Poordad, MD, on Ethnic Differences in Telaprevir Treatment Effect
February 17, 2012
In this video Fred Poordad, MD, Chief of Hepatology and Liver Transplantation at the Comprehensive Transplant Center at Cedars-Sinai Medical Center evaluates the effect of race on the response to treatment and viral resistance profiles with telaprevir combination therapy.
Since pancreatic cancer is so rare, screening among the general population is not worthwhile, according to Randall Brand, MD. Instead, physicians should only screen those individuals considered "high risk."